Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine plus low-dose prednisone versus medium-dose prednisone in pulmonary sarcoidosis
2021-001834-20Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Dec 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in pulmonary sarcoidosis and sarcoidosis comparing Hydroxychloroquine plus low-dose prednisone with Medium-dose prednisone (2 arms). Started Dec 2021; status: active.
02
Drugs
hydroxychloroquineprednisone
03
Conditions
pulmonary sarcoidosissarcoidosis
Beyond the preview
Go deeper on 2021-001834-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001834-20.